Segall Bryant & Hamill LLC Increases Stake in Vericel Co. (NASDAQ:VCEL)

Segall Bryant & Hamill LLC raised its holdings in shares of Vericel Co. (NASDAQ:VCEL) by 49.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 115,334 shares of the biotechnology company’s stock after purchasing an additional 38,031 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in Vericel were worth $4,873,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. International Assets Investment Management LLC lifted its stake in shares of Vericel by 4,126.7% during the 3rd quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 619 shares in the last quarter. CWM LLC raised its holdings in Vericel by 319.0% during the 2nd quarter. CWM LLC now owns 662 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 504 shares during the period. Farther Finance Advisors LLC boosted its holdings in shares of Vericel by 48.1% in the third quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 405 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Vericel by 22.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock valued at $77,000 after purchasing an additional 322 shares in the last quarter. Finally, Meeder Asset Management Inc. bought a new stake in shares of Vericel during the 3rd quarter valued at $92,000.

Insider Activity at Vericel

In other news, Director Steven C. Gilman sold 5,833 shares of the firm’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $40.35, for a total value of $235,361.55. Following the transaction, the director now owns 11,000 shares in the company, valued at approximately $443,850. This trade represents a 34.65 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Dominick Colangelo sold 17,500 shares of the company’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $41.38, for a total transaction of $724,150.00. Following the sale, the chief executive officer now owns 220,937 shares of the company’s stock, valued at $9,142,373.06. This represents a 7.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 29,166 shares of company stock valued at $1,200,764. Insiders own 5.20% of the company’s stock.

Wall Street Analysts Forecast Growth

VCEL has been the subject of several analyst reports. Canaccord Genuity Group assumed coverage on Vericel in a research note on Friday, August 9th. They issued a “buy” rating and a $57.00 target price for the company. Canaccord Genuity Group reaffirmed a “buy” rating and set a $60.00 target price on shares of Vericel in a report on Tuesday. TD Cowen boosted their price target on shares of Vericel from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, August 27th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Vericel in a research report on Friday, November 8th. Finally, StockNews.com upgraded Vericel from a “sell” rating to a “hold” rating in a research note on Friday, November 8th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, Vericel currently has a consensus rating of “Moderate Buy” and a consensus target price of $58.14.

Vericel Trading Up 4.2 %

VCEL opened at $59.11 on Friday. The stock has a market capitalization of $2.92 billion, a P/E ratio of 985.33 and a beta of 1.66. Vericel Co. has a 12-month low of $32.31 and a 12-month high of $60.15. The stock has a 50-day moving average price of $46.13 and a 200-day moving average price of $47.02.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.03. The business had revenue of $57.91 million for the quarter, compared to analysts’ expectations of $55.32 million. Vericel had a net margin of 1.56% and a return on equity of 1.48%. On average, equities research analysts predict that Vericel Co. will post 0.13 EPS for the current year.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.